Portal de Periódicos da CAPES

Venous Thromboembolic Disease

2013; National Comprehensive Cancer; Volume: 11; Issue: 11 Linguagem: Inglês

10.6004/jnccn.2013.0163

1540-1413

Michael B. Streiff, Paula Bockenstedt, Spero R. Cataland, C Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul C. Hendrie, Björn Holmström, Nicole M. Kuderer, Jason T. Lee, Michael Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole R. McMillian, Maoko Naganuma,

Peripheral Artery Disease Management

Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.